论文部分内容阅读
目的 :探讨酮替芬联合黄芪颗粒治疗小儿咳嗽变异性哮喘的临床疗效。方法 :选择2012年5月~2014年6月我院儿科收治的咳嗽变异性哮喘患儿120例,将其随机分为观察组和对照组,每组60例,对照组给予酮替芬治疗,观察组在对照组基础上加用黄芪颗粒,两组均治疗两个月,比较两组临床疗效、治疗前后免疫功能变化以及不良反应。结果 :观察组治疗总有效率为93.33%,对照组治疗总有效率为80.00%,两组比较,差异具有统计学意义;观察组治疗后Ig A较治疗前显著升高,Ig E较治疗前显著降低;而对照组治疗前后各体液免疫指标变化均无差异;观察组治疗后CD4+、CD4+/CD8+较治疗前显著升高,而治疗前后CD8+水平无变化;对照组各细胞免疫指标治疗前后均无变化;观察组不良反应发生率3.33%,对照组不良反应发生率13.33%,两组不良反应发生率比较,差异具有统计学意义。结论 :酮替芬联合黄芪颗粒治疗小儿咳嗽变异性哮喘的临床疗效显著,且能够显著改善患儿的机体免疫功能,减少不良反应的发生率,值得临床推广运用。
Objective: To investigate the clinical efficacy of ketotifen combined with Astragalus Granules in the treatment of children with cough variant asthma. Methods: A total of 120 children with cough variant asthma admitted to our hospital from May 2012 to June 2014 were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with ketotifen, The observation group was given Astragalus membranaceus on the basis of the control group. Both groups were treated for two months. The clinical efficacy, immune function changes and adverse reactions before and after treatment were compared between the two groups. Results: The total effective rate of the observation group was 93.33%, the total effective rate of the control group was 80.00%, the difference between the two groups was statistically significant; the Ig A of the observation group was significantly higher than that before treatment, While the control group had no difference in the indexes of humoral immunity before and after treatment. The levels of CD4 +, CD4 + / CD8 + in the observation group after treatment were significantly higher than those before treatment, but there was no change in the level of CD8 + before and after treatment. The incidence of adverse reactions in the observation group was 3.33%, the incidence of adverse reactions in the control group was 13.33%. There was significant difference between the two groups in the incidence of adverse reactions. Conclusion: Ketotifen combined with Astragalus Granules in children with cough variant asthma clinical efficacy significantly, and can significantly improve children’s immune function and reduce the incidence of adverse reactions, worthy of clinical promotion and use.